carubicin and Hodgkin-Disease

carubicin has been researched along with Hodgkin-Disease* in 3 studies

Reviews

1 review(s) available for carubicin and Hodgkin-Disease

Article	Year
The anthracycline antineoplastic drugs. The New England journal of medicine, 1981, Jul-16, Volume: 305, Issue:3 Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Female; Glycosides; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Naphthacenes; Ovarian Neoplasms; Sarcoma	1981

Trials

1 trial(s) available for carubicin and Hodgkin-Disease

Article	Year
[Phase II study of KRN8602 (MX2) for malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7 We performed a clinical phase II study of KRN8602, a new anthracycline derivative, for relapsed or recurrent malignant lymphoma. KRN8602 was given at doses of 12-15 mg/m2 for 3 consecutive days, repeating every 3-4 weeks. Among 44 patients entered into the study, 36 were evaluable for safety, and 35 were evaluable for efficacy. The response rate was 18.2% (6PR/33) for non-Hodgkin's lymphoma and 0% (0/2) for Hodgkin's disease. Major toxicities were bone marrow suppression and gastrointestinal toxicity. Leukopenia was observed in 77.8%, thrombocytopenia in 44.4%, hemoglobin decrease in 44.4%, nausea and vomiting in 94.4% and anorexia in 80.6%. However, all toxicities were clinically manageable. Topics: Anorexia; Antibiotics, Antineoplastic; Carubicin; Drug Administration Schedule; Hodgkin Disease; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Nausea; Thrombocytopenia; Vomiting	1998

Article

Year

[Phase II study of KRN8602 (MX2) for malignant lymphoma].

Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7

We performed a clinical phase II study of KRN8602, a new anthracycline derivative, for relapsed or recurrent malignant lymphoma. KRN8602 was given at doses of 12-15 mg/m2 for 3 consecutive days, repeating every 3-4 weeks. Among 44 patients entered into the study, 36 were evaluable for safety, and 35 were evaluable for efficacy. The response rate was 18.2% (6PR/33) for non-Hodgkin's lymphoma and 0% (0/2) for Hodgkin's disease. Major toxicities were bone marrow suppression and gastrointestinal toxicity. Leukopenia was observed in 77.8%, thrombocytopenia in 44.4%, hemoglobin decrease in 44.4%, nausea and vomiting in 94.4% and anorexia in 80.6%. However, all toxicities were clinically manageable.

Topics: Anorexia; Antibiotics, Antineoplastic; Carubicin; Drug Administration Schedule; Hodgkin Disease; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Nausea; Thrombocytopenia; Vomiting

1998

Other Studies

1 other study(ies) available for carubicin and Hodgkin-Disease

Article	Year
[Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline]. Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:7 Phase I clinical trial of a new semi-synthetic morpholino anthracycline derivative, KRN8602, was performed. Sixteen patients with advanced malignant neoplasms refractory to standard chemotherapies received 27 courses at doses ranging from 1.5 mg/m2/day to 18 mg/m2/day by bolus injection for three consecutive days. The dose limiting toxicity was leukopenia, and a maximally tolerated dose was 18 mg/m2/day (day 1-3). The recommended dose and schedule for a phase II study is determined to be 12 mg/m2/day for three consecutive days at 3-4 weeks intervals. Among non-hematologic toxicities, nausea and vomiting were severe, but stomatitis and alopecia were rarely observed. Clinical signs of cardiotoxicity were not seen. Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carubicin; Drug Evaluation; Female; Hodgkin Disease; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia	1989

Article

Year

[Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].

Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:7

Phase I clinical trial of a new semi-synthetic morpholino anthracycline derivative, KRN8602, was performed. Sixteen patients with advanced malignant neoplasms refractory to standard chemotherapies received 27 courses at doses ranging from 1.5 mg/m2/day to 18 mg/m2/day by bolus injection for three consecutive days. The dose limiting toxicity was leukopenia, and a maximally tolerated dose was 18 mg/m2/day (day 1-3). The recommended dose and schedule for a phase II study is determined to be 12 mg/m2/day for three consecutive days at 3-4 weeks intervals. Among non-hematologic toxicities, nausea and vomiting were severe, but stomatitis and alopecia were rarely observed. Clinical signs of cardiotoxicity were not seen.

Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carubicin; Drug Evaluation; Female; Hodgkin Disease; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia

1989